In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/ L) occurred in 29.4% (i. e. very common) of the patients in the irbesartan 300 mg group and 22% of the patients in the placebo group.